Odactra DERMATOPHAGOIDES PTERONYSSINUS and DERMATOPHAGOIDES FARINAE 6 [arb'U]/1; 6 [arb'U]/1 Tablet, 5-count — NDC 52709-1701-05 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Odactra DERMATOPHAGOIDES PTERONYSSINUS and DERMATOPHAGOIDES FARINAE 6 [arb'U]/1; 6 [arb'U]/1 Tablet, 5-count — NDC 52709-1701-5 (Billing 52709-1701-05)

by ALK-Abello A S · 1 BLISTER PACK in 1 CARTON / 5 TABLET in 1 BLISTER PACK

This is a package of 5 tablets of Odactra DERMATOPHAGOIDES PTERONYSSINUS and DERMATOPHAGOIDES FARINAE 6 [arb'U]/1; 6 [arb'U]/1 Tablet from ALK-Abello A S, first listed with the FDA Jan 2018 and currently FDA-listed.

NDC 52709-1701-05
🏷️ FDA NDC (as labeled) 52709-1701-5 billing pads the package segment with a zero
This package
Contains5-count Pack sizes2 compare ↓
Brand FDA-listed Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Nov 19, 2026 · this listing last changed Nov 19, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

NDC database record

One package, one record: these facts belong to NDC 52709-1701-5 alone.

Record
FDA NDC Directory package listing · Standardized allergenic
Code segments
52709 labeler · 1701 product · 5 package
Package marketed since
Jan 1, 2018
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Barcode (UPC-A, from the NDC)
3 5270917015 8
FDA record last changed
Nov 19, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 52709-1701-5
Product NDC 52709-1701
11-digit billing NDC 52709170105
Application # BLA125592
SPL Set ID 71ca220d-78d5-47d4-be84-8d6e844b24b3
Established class (EPC) Antigens
Physiologic effect Cell-mediated Immunity; Increased Histamine Release; Increased IgG Production
Chemical class Allergens; Dermatophagoides
DEA schedule Non-controlled
Marketing category BLA
Marketing status FDA-listed
FDA listing status Listed (active directory)
Marketing start 2018-01-01
Route SUBLINGUAL
Dosage form TABLET
Substance DERMATOPHAGOIDES PTERONYSSINUS; DERMATOPHAGOIDES FARINAE
Biologic (Purple Book) 351(a)

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 20109902220740
GPI class Odactra
GCN Seq No 076750
GCN 42527
HICL code 034376
Ingredient (HICL) Allergenic Extract, Mite-D.farinae-D.pteronyssinus,Standard
HIC1 code W
Therapeutic class — broad (HIC1) Anti-Infecting Agents
HIC2 code W7
Therapeutic class — intermediate (HIC2) Biologicals
HIC3 code W7W
Therapeutic class — specific (HIC3) Allergenic Extracts, Therapeutic
AHFS code 80:02.00.00
AHFS class Allergenic Extracts (Therapeutic)
FDB label name ODACTRA 12 SQ-HDM SL TABLET
FDB brand name Odactra
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 076750
  • GCN: 42527
  • GPI-14 (Medi-Span): 20109902220740
  • HICL (First Databank): 034376
  • AHFS class code: 80:02.00.00
Why two NDCs? The FDA registers this code as 52709-1701-5 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 52709-1701-05. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name ODACTRA 12 SQ-HDM SL TABLET Ingredient Allergenic Extract, Mite-D.farinae-D.pteronyssinus,Standard
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eachPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Try another pack size: 30 tablets
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
52709-1701-03 52709-1701-3 Main listing 3 BLISTER PACK in 1 CARTON / 10 TABLET in 1 BLISTER PACK Inner NDC 52709-1701-1 · each blister pack (10 tablets) $11.71 / ea $351.32 2018-01-01 — Active
52709-1701-05 You're viewing this 1 BLISTER PACK in 1 CARTON / 5 TABLET in 1 BLISTER PACK — — 2018-01-01 — Active

This pack shows little to no recent Medicaid volume — a different pack size carries most fills. See all packs ↓

Pack size FAQ

What quantity is in this package?
This is a 5-count package — 1 blister pack in 1 carton / 5 tablet in 1 blister pack.
How does this package differ from NDC 52709-1701-03?
Both are Odactra DERMATOPHAGOIDES PTERONYSSINUS and DERMATOPHAGOIDES FARINAE 6 [arb'U]/1; 6 [arb'U]/1 Tablet — the drug itself is identical. This page's package is the 5-count one, while NDC 52709-1701-03 is the 30 tablets package.
What NDC number is used to bill for this package of Odactra DERMATOPHAGOIDES PTERONYSSINUS and DERMATOPHAGOIDES FARINAE 6 [arb'U]/1; 6 [arb'U]/1 Tablet?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Odactra 6 [arb'U]/1; 6 [arb'U]this 52709-1701-05 ALK-Abello 5 tablets — — FDA listed —
About this product: this is a biologic. Biologics don't have small-molecule generics — competition comes from FDA-licensed biosimilars (shown above), not generics.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & biosimilar status

🏛️
2017
First FDA approval
Mar 2017
📍
2026
Currently FDA-listed
9 years listed
🛡️
2029
Latest patent/protection listed
not a guaranteed launch date
🧬Biologic — competition comes from biosimilars

Biologics have no small-molecule generics; biosimilar competition is tracked in the FDA Purple Book.

🛡️ Latest patent/protection date listed: FDA patent/protection data lists protections through Mar 2029. This may affect when biosimilars become widely available, but it is not a guaranteed launch date.
📅 FDA approved Mar 1, 2017 ⏳ ~2.3 yr to latest listed protection

Why the date isn’t exact: Biosimilar timing can change because patents may be challenged, settled, licensed, added or removed, and litigation can move the real date earlier or later.

Patents & exclusivity — FDA Purple Book
Exclusivity RefProduct
2017 2019 2021 2023 2025 2027 2029
Today
LOE
Biologic patent Exclusivity
🏛️Reference-product exclusivity
A flat 12 years of FDA market protection from first licensure. No biosimilar can be licensed before it ends — regardless of patents.
🧪Listed biologic patents
Patents the reference maker lists covering the molecule, formulation, or manufacturing. A biosimilar generally can’t launch until these resolve.
🔁Interchangeability
An interchangeable biosimilar may be substituted at the pharmacy (state laws vary). The first one can earn its own exclusivity period.
🛈 What do these terms mean?
Biologic patent
A patent the reference product’s maker has publicly listed. A biosimilar generally can’t launch until these expire — unless they’re invalidated or resolved in a settlement.
Reference-product exclusivity
A flat 12 years of FDA market protection from the biologic’s first licensure (the BPCIA). No biosimilar can be licensed before it ends, regardless of patents.
Interchangeable exclusivity
The first interchangeable biosimilar can earn a period as the only interchangeable version (pharmacists can substitute it without the prescriber).
Earliest biosimilar (LOE)
The latest of all the dates above — the soonest a biosimilar can realistically reach the market. Litigation and settlements can move it earlier.

Biologics have no small-molecule “generics” — competition comes from FDA-licensed biosimilars, tracked in the FDA Purple Book.

FDA exclusivity
CodeWhat it grantsExpires
RefProductReference-product exclusivity (12-year, BPCIA) — no biosimilar can be licensed before this dateMar 1, 2029
Common questions
Is there a biosimilar for ODACTRA 12 SQ-HDM SL TABLET?
No FDA-licensed biosimilar is currently listed for this biologic in the FDA Purple Book.
Why do different websites show different biosimilar dates?
Biosimilar availability isn’t based on one single date. Some sources use the reference-product exclusivity, some use the last listed patent, and patent litigation, settlements, and licenses can all change the real-world launch date. This page shows the underlying Purple Book dates so you can see why estimates differ.
Can a biosimilar launch before the last patent expires?
Sometimes. A biosimilar maker may settle with the reference manufacturer or receive a license to launch earlier. In other cases, the last listed protection delays competition.
What does “current Purple Book estimate” mean?
It means we’re using the latest patent and exclusivity dates currently listed in the FDA Purple Book. It is not a guaranteed launch date.
What does “FDA listed” mean?
It means the product appears in the FDA’s official directory. That’s a good sign a product exists for the U.S. market, but on its own it does not confirm a pharmacy can get it today. Where we have recent retail pricing data, we label it “Availability likely” instead.
What does a patent or protection date mean here?
It’s the latest date currently listed in the FDA Purple Book for a patent or exclusivity on the reference biologic. It can affect when a biosimilar becomes widely available — but it is not a guaranteed launch date. Settlements and licenses can move the real date earlier or later.
Built from the FDA Purple Book Patent List (patents the reference-product sponsor has publicly listed under the BPCIA) plus reference-product exclusivity. Biosimilars cannot launch until these clear; patent litigation and settlements can shift the real date. Biologics have no small-molecule generics — competition comes from FDA-licensed biosimilars, not the Orange Book.
Where does this data come from?
Patents and exclusivity from the FDA Purple Book (biologics), refreshed from public FDA data. Biosimilar launch timing is an estimate, not a guarantee.

What it looks like

Color white
ShapeRound
Size12 mm
ScoringNot scored
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 3OWL53L36A
    A natural sugar alcohol derived from seaweed or synthesized in the lab. It's used as a filler to add bulk, a sweetener in sugar-free formulas, and a disintegrant to help tablets break apart in the stomach.
  • UNII JSM64OJO9B
    A protein derived from fish or shellfish, used as a capsule material or binder in medicines. It helps hold ingredients together and forms the outer shell of soft gel capsules.
  • UNII AHQ60JKI5D
    A protein derived from fish or marine animals, used as a capsule material or binder in medications. Its high molecular weight helps form sturdy capsule shells that contain and protect the active drug inside.
  • UNII 55X04QC32I
    A strong alkaline chemical used to adjust and maintain the pH balance of liquid medicines. It helps keep the medicine stable and ensures it stays effective during storage.

4 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerALK-Abello A S
FDA applicationBLA125592 (BLA)
Labeler code52709
First marketedJan 2018
Product typeStandardized Allergenic
Portfolio3 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full FDA label FDA SPL

The complete FDA label for this product, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🚨 Boxed Warning ~1 min read ▾

WARNING: SEVERE ALLERGIC REACTIONS ODACTRA can cause life-threatening allergic reactions such as anaphylaxis and severe laryngopharyngeal restriction. ( 5.1 ) Do not administer ODACTRA to patients with severe, unstable or uncontrolled asthma. ( 4 ) Observe patients in the office for at least 30 minutes following the initial dose.

( 5.1 ) Prescribe epinephrine, instruct and train patients or parents/guardians on its appropriate use, and instruct patients or parents/guardians to seek immediate medical care upon its use. ( 5.1 ) ODACTRA may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious allergic reaction. ( 5.1 ) ODACTRA may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers.

( 5.1 ) WARNING: SEVERE ALLERGIC REACTIONS See full prescribing information for complete boxed warning. • ODACTRA can cause life-threatening allergic reactions such as anaphylaxis and severe laryngopharyngeal restriction . ( 5.1 ) • Do not administer ODACTRA to patients with severe, unstable or uncontrolled asthma . ( 4 ) • Observe patients in the office for at least 30 minutes following the initial dose.

( 5.1 ) • Prescribe epinephrine, instruct and train patients or parents/guardians on its appropriate use, and instruct patients or parents/guardians to seek immediate medical care upon its use. ( 5.1 ) • ODACTRA may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious allergic reaction. ( 5.1 ) • ODACTRA may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers.

( 5.1 )

🎯 Indications and Usage 152 words ▾

1 INDICATIONS AND USAGE ODACTRA ™ is an allergen extract indicated as immunotherapy for the treatment of house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive in vitro testing for IgE antibodies to Derma t ophagoides farinae or Dermatophagoides pteronyssinus house dust mites, or by positive skin testing to licensed house dust mite allergen extracts. ODACTRA is approved for use in individuals 5 through 65 years of age. ODACTRA is not indicated for the immediate relief of allergic symptoms.

ODACTRA is an allergen extract indicated as immunotherapy for the treatment of house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive in vitro testing for IgE antibodies to Dermatophagoides farina e or Dermatophagoides pteronyssinus house dust mites or by positive skin testing to licensed house dust mite allergen extracts. ODACTRA is approved for use in individuals 5 through 65 years of age. ( 1 )

⏱️ Dosage and Administration ~1 min read ▾

2 DOSAGE AND ADMINISTRATION Administer sublingually. Administer sublingually ( 2 ) One tablet daily. ( 2.1 ) Place the tablet immediately under the tongue where it will dissolve within 10 seconds.

Allow it to remain there until completely dissolved. Do not swallow for at least 1 minute. ( 2.2 ) Administer the first dose of ODACTRA under the supervision of a healthcare professional with experience in the diagnosis and treatment of allergic diseases.

Observe patients in the office for at least 30 minutes following the initial dose. ( 2.2 )

2.1Dos e One ODACTRA tablet daily. 2. 2 Administration Administer the first dose of ODACTRA in a healthcare setting under the supervision of a healthcare professional with experience in the diagnosis and treatment of allergic diseases.

After receiving the first dose of ODACTRA, observe the patient for at least 30 minutes to monitor for signs or symptoms of a severe systemic or a severe local allergic reaction. If the patient tolerates the first dose, the patient may take subsequent doses at home. The patient should administer ODACTRA as follows: Take the tablet from the blister unit after carefully removing the foil with dry hands.

Place the tablet immediately under the tongue where it will dissolve within 10 seconds. Do not swallow for at least 1 minute. Wash hands after handling the tablet.

Do not take the tablet with food or beverage. Food or beverage should not be taken for 5 minutes after taking the tablet. Data regarding the safety of restarting treatment after missing a dose of ODACTRA are limited.

In the clinical studies, treatment interruptions for up to seven days were allowed. Prescribe epinephrine to patients prescribed ODACTRA and instruct patients (or their parents/guardians) in the proper use of epinephrine [see Warnings and Precautions ( 5.1 ) ] .

💊 Dosage Forms and Strengths 67 words ▾

3 DOSAGE FORMS AND STRENGTHS ODACTRA is available as 12 SQ-HDM* sublingual tablets that are white to off-white, circular with a debossed pentagon detail on one side. *SQ-HDM is the dose unit for ODACTRA. SQ is a method of standardization of biological potency, major allergen content and complexity of the allergen extract. HDM is an abbreviation for house dust mite. Sublingual tablet, 12 SQ-HDM. ( 3 )

⛔ Contraindications 104 words ▾

4 CONTRAINDICATIONS ODACTRA is contraindicated in patients with: Severe, unstable or uncontrolled asthma A history of any severe systemic allergic reaction A history of any severe local reaction after taking any sublingual allergen immunotherapy A history of eosinophilic esophagitis Hypersensitivity to any of the inactive ingredients contained in this product [see Description ( 11 )] Severe, unstable or uncontrolled asthma. ( 4 ) History of any severe systemic allergic reaction or any severe local reaction to sublingual allergen immunotherapy.

( 4 ) A history of eosinophilic esophagitis. ( 4 ) Hypersensitivity to any of the inactive ingredients contained in this product. ( 4 )

⚠️ Warnings and Cautions ~2 min read ▾

5 WARNINGS AND PRECAUTIONS Inform patients or parents/guardians of the signs and symptoms of serious allergic reactions and instruct them to seek immediate medical care and discontinue therapy should any of these occur. ( 5.1 ) In case of oral inflammation or wounds, stop treatment with ODACTRA to allow complete healing of the oral cavity. ( 5.6 )

5.1Severe Allergic Reactions ODACTRA can cause systemic allergic reactions including anaphylaxis which may be life-threatening. In addition, ODACTRA can cause severe local reactions, including laryngopharyngeal swelling, which can compromise breathing and be life-threatening. Allergic reactions may require treatment with epinephrine.

Prescribe epinephrine to patients receiving ODACTRA. Instruct patients or their parents/guardians to recognize the signs and symptoms of a severe allergic reaction and in the proper use of emergency epinephrine. Instruct patients or their parents/guardians to seek immediate medical care and to stop treatment with ODACTRA upon use of epinephrine [see Patient Counseling Information ( 17 ) ].

See Prescribing Information for epinephrine for complete information. ODACTRA may not be suitable for patients with certain medical conditions that may reduce the ability to survive a serious allergic reaction or that may increase the risk of adverse reactions after epinephrine administration. Examples of these medical conditions include but are not limited to: markedly compromised lung function (either chronic or acute); severe mast cell disorder; or cardiovascular disease including unstable angina, recent myocardial infarction, significant arrhythmia, and uncontrolled hypertension.

In addition, ODACTRA may not be suitable for patients who are taking medications that can potentiate or inhibit the effects of epinephrine (see Prescribing Information for epinephrine for information on drug interactions). Administer the initial dose of ODACTRA in a healthcare setting under the supervision of a healthcare professional with experience in the diagnosis and treatment of allergic diseases and prepared to manage a life-threatening systemic or local allergic reaction. Observe patients in the office for at least 30 minutes following the initial dose of ODACTRA.

5. 2 Upper Airway Compromise ODACTRA can cause local reactions in the mouth or throat that could compromise the upper airway [see Adverse Reactions ( 6.1 )] . Consider discontinuation of ODACTRA in patients who experience persistent and escalating adverse reactions in the mouth or throat.

5. 3 Eosinophilic Esophagitis Eosinophilic esophagitis has been reported in association with sublingual tablet immunotherapy [see Contraindications ( 4 )] . Discontinue ODACTRA and consider a diagnosis of eosinophilic esophagitis in patients who experience severe or persistent gastroesophageal symptoms including dysphagia or chest pain.

5. 4 Asthma Withhold immunotherapy with ODACTRA if the patient is experiencing an acute asthma exacerbation. Re-evaluate patients who have recurrent asthma exacerbations and consider discontinuation of ODACTRA.

5. 5 Concomitant Allergen Immunotherapy ODACTRA has not been studied in participants who are receiving concomitant allergen immunotherapy. Concomitant dosing with other allergen immunotherapy may increase the likelihood of local or systemic adverse reactions to either subcutaneous or sublingual allergen immunotherapy.

5. 6 Oral Conditions Stop treatment with ODACTRA to allow complete healing of the oral cavity in patients with oral inflammation (e.g., oral lichen planus, mouth ulcers, or thrush) or oral wounds, such as those following oral surgery, tooth loss or dental extraction.

🤒 Adverse Reactions ~3 min read ▾

6 ADVERSE REACTIONS The most common solicited adverse reactions reported in ≥10% of adult participants (18 through 65 years of age) treated with ODACTRA were: throat irritation/tickle, itching in the mouth, itching in the ear, swelling of the uvula/back of the mouth, swelling of the lips, swelling of the tongue, tongue pain, nausea, throat swelling, stomach pain, tongue ulcer/sore on the tongue, mouth ulcer/sore in the mouth, and food tastes different. The most common solicited adverse reactions reported in ≥10% of adolescent participants (12 through 17 years of age) treated with ODACTRA were: throat irritation/tickle, itching in the mouth, itching in the ear, tongue pain, stomach pain, swelling of the uvula/back of the mouth, swelling of the lips, swelling of the tongue, throat swelling, nausea, tongue ulcer/sore on the tongue, and mouth ulcer/sore in the mouth, and diarrhea.

The most common solicited adverse reactions reported in ≥10% of pediatric participants (5 through 11 years of age) treated with ODACTRA were itching in the mouth, throat irritation/tickle, itching in the ear, stomach pain, swelling of the lips, tongue pain, food tastes different, nausea (feel like throwing up), swelling in the back of the mouth, swelling of the tongue, and mouth ulcer. The most common solicited adverse reactions reported in ≥10% of adult participants (18 through 65 years of age) treated with ODACTRA were: throat irritation/tickle, itching in the mouth, itching in the ear, swelling of the uvula/back of the mouth, swelling of the lips, swelling of the tongue, tongue pain, nausea, throat swelling, stomach pain, tongue ulcer/sore on the tongue, mouth ulcer/sore in the mouth, and food tastes different.

( 6.1 ) The most common solicited adverse reactions reported in ≥10% of adolescent participants (12 through 17 years of age) treated with ODACTRA were: throat irritation/tickle, itching in the mouth, itching in the ear, tongue pain, stomach pain, swelling of the uvula/back of the mouth, swelling of the lips, swelling of the tongue, throat swelling, nausea, tongue ulcer/sore on the tongue, and mouth ulcer/sore in the mouth, and diarrhea. ( 6.1 ) The most common solicited adverse reactions reported in ≥10% of pediatric participants (5 through 11 years of age) treated with ODACTRA were: itching in the mouth, throat irritation/tickle, itching in the ear, stomach pain, swelling of the lips, tongue pain, food tastes different, nausea (feel like throwing up), swelling in the back of the mouth, swelling of the tongue, and mouth ulcer.

( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact ALK-Abelló Inc., a subsidiary of ALK-Abelló A/S, at 1-855-216-6497 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

6.1Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Adults (18 through 65 years of age) In four double-blind, placebo-controlled, randomized clinical studies, a total of 1279 participants with house dust mite-induced allergic rhinitis, with or without conjunctivitis, 18 through 65 years of age was treated with at least one dose of ODACTRA 12 SQ-HDM.

Of participants treated with ODACTRA in the four studies, 50% had mild to moderate asthma and 71% were polysensitized to other allergens in addition to HDM, including trees, grasses, weeds, molds, and animal danders. The study population was 88% White, 6% African American, 4% Asian and 55% female. Study 1 (NCT01700192) was a randomized, double-blind, placebo-controlled study conducted in the US and Canada evaluating ODACTRA in 1482 participants 12 years of age and older with house dust mite-induced allergic rhinitis with or without conjunctivitis.

Of the 1482 participants, 640 participants 18 through 65 years of age received at least one dose of ODACTRA, with a… [Excerpted — this section continues on DailyMed.]

👥 Use in Specific Populations ~1 min read ▾

8 USE IN SPECIFIC POPULATIONS

8.1Pregnancy Risk Summary All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Available data on ODACTRA administered to pregnant women are insufficient to inform associated risks in pregnancy.

In an embryo/fetal developmental toxicity study performed in mice, administration of ODACTRA during gestation did not reveal adverse developmental outcomes in fetuses [ see Data ( 8.1 ) ]. Data Animal Data In a developmental toxicity study, the effect of ODACTRA on embryo/fetal development was evaluated in mice. Animals were administered ODACTRA subcutaneously daily from day 6 to day 17 of the gestation period at doses up to 5 times the human sublingual dose.

There were no ODACTRA-related post-implantation losses, fetal malformations or variations. 8. 2 Lactation Risk Summary It is not known whether ODACTRA is excreted in human milk.

Data are not available to assess the effects of ODACTRA on the breastfed child or on milk production and excretion in the nursing woman. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ODACTRA and any potential adverse effects on the breastfed child from ODACTRA or from the underlying maternal condition.

8.4Pediatric Use The safety and effectiveness of ODACTRA have been established in individuals 5 through 17 years of age with HDM-induced allergic rhinitis, with or without conjunctivitis. [ s ee Adverse Reactions ( 6.1 ) and C linical S tudies ( 14 ) ] . The safety and effectiveness have not been established in individuals below 5 years of age.

8.5Geriatric Use Safety and effectiveness have not been established in individuals older than 65 years of age.

🤰 Pregnancy 145 words ▾

8.1Pregnancy Risk Summary All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Available data on ODACTRA administered to pregnant women are insufficient to inform associated risks in pregnancy.

In an embryo/fetal developmental toxicity study performed in mice, administration of ODACTRA during gestation did not reveal adverse developmental outcomes in fetuses [ see Data ( 8.1 ) ]. Data Animal Data In a developmental toxicity study, the effect of ODACTRA on embryo/fetal development was evaluated in mice. Animals were administered ODACTRA subcutaneously daily from day 6 to day 17 of the gestation period at doses up to 5 times the human sublingual dose.

There were no ODACTRA-related post-implantation losses, fetal malformations or variations.

🧒 Pediatric Use 61 words ▾

8.4Pediatric Use The safety and effectiveness of ODACTRA have been established in individuals 5 through 17 years of age with HDM-induced allergic rhinitis, with or without conjunctivitis. [ s ee Adverse Reactions ( 6.1 ) and C linical S tudies ( 14 ) ] . The safety and effectiveness have not been established in individuals below 5 years of age.

🧓 Geriatric Use 18 words ▾

8.5Geriatric Use Safety and effectiveness have not been established in individuals older than 65 years of age.

🆘 Overdosage 80 words ▾

10 OVERDOSAGE Symptoms of overdose may include hypersensitivity reactions such as systemic allergic reactions or severe local allergic reactions [see Warnings and Precautions ( 5.1 )] . In case of severe adverse reactions such as angioedema, difficulty in swallowing, difficulty in breathing, changes in voice, or feeling of fullness in the throat, immediate medical evaluation is needed. These reactions should be treated as medically indicated, including the use of epinephrine as appropriate [see Warnings and Precautions ( 5.1 )] .

🧬 Clinical Pharmacology 20 words ▾

12 CLINICAL PHARMACOLOGY

12.1Mechanism of Action The precise mechanisms of action of allergen immunotherapy have not been fully established.

🧬 Mechanism of Action 17 words ▾

12.1Mechanism of Action The precise mechanisms of action of allergen immunotherapy have not been fully established.

📦 How Supplied / Storage and Handling 59 words ▾

16 HOW SUPPLIED/STORAGE AND HANDLING ODACTRA 12 SQ-HDM tablets are white to off-white, circular freeze-dried sublingual tablets with a debossed pentagon detail on one side. ODACTRA is supplied as follows: 3 blister packages of 10 tablets (30 tablets total). NDC 52709-1701-3 Store at controlled room temperature, 20ºC-25ºC (68ºF-77ºF). Store in the original package until use to protect from moisture.

📋 Description 88 words ▾

11 DESCRIPTION ODACTRA tablets contain house dust mite allergen extract from Dermatophagoides farinae and Dermatophagoides pteronyssinus . ODACTRA is a sublingual tablet that dissolves within 10 seconds. ODACTRA is available as a tablet of 12 SQ-HDM [6 SQ-HDM D. farina e and 6 SQ-HDM D. pteronyssinus ].

Each tablet contains a 1:1:1:1 potency ratio of D. farinae group 1 allergen, D. farinae group 2 allergen, D. pteronyssinus group 1 allergen, and D. pteronyssinus group 2 allergen. Inactive ingredients: gelatin NF (fish source), mannitol USP, and sodium hydroxide NF.

💬 Information for Patients ~2 min read ▾

17 PATIENT COUNSELING INFORMATION Advise patients (or their parents/guardians) to read the FDA-approved patient labeling ( Medication Guide ) and to keep ODACTRA and all medicines out of the reach of children. Severe Allergic Reactions Advise patients (or their parents/guardians) that ODACTRA may cause life-threatening systemic or local allergic reactions, including anaphylaxis. Educate patients (or their parents/guardians) about the signs and symptoms of these allergic reactions [see Warnings and Precautions ( 5.1 )] .

The signs and symptoms of a severe allergic reaction may include: syncope, dizziness, hypotension, tachycardia, dyspnea, wheezing, bronchospasm, chest discomfort, cough, abdominal pain, vomiting, diarrhea, rash, pruritus, flushing, and urticaria. Ensure that patients (or their parents/guardians) have epinephrine and instruct patients (or their parents/guardians) in its proper use. Instruct patients (or their parents/guardians) who experience a severe allergic reaction to seek immediate medical care, discontinue ODACTRA, and resume treatment only when advised by a healthcare professional to do so [ s ee Warnings and Precautions ( 5.1 ). ] Advise patients to read the patient information for epinephrine.

Inform patients (or their parents/guardians) that the first dose of ODACTRA must be administered in a healthcare setting under the supervision of a healthcare professional and that they will be monitored for at least 30 minutes to watch for signs and symptoms of life-threatening systemic or local allergic reaction [see Warnings and Precautions ( 5.1 )] . Because of the risk of upper airway compromise, instruct patients (or their parents/guardians) with persistent and escalating adverse reactions in the mouth or throat to discontinue ODACTRA and to contact their healthcare professional [ s ee Warnings and Precautions ( 5.2 )] .

Because of the risk of eosinophilic esophagitis, instruct patients (or their parents/guardians) with severe or persistent symptoms of esophagitis to discontinue ODACTRA and to contact their healthcare professional [ s ee Warnings and Precautions ( 5.3 )] . Asthma Instruct patients (or their parents/guardians) with asthma that if they have difficulty breathing or if their asthma becomes difficult to control, they should stop taking ODACTRA and contact their healthcare professional immediately [see Warnings and Precautions ( 5.4 ) ] .

Administration Instructions Instruct patients (or their parents/guardians) to carefully remove the foil from the blister unit with dry hands and then take the sublingual tablet immediately by placing it under the tongue where it will dissolve within 10 seconds. Instruct patients to avoid swallowing for at least 1 minute. Also instruct patients to wash their hands after handling the tablet, and to avoid food or beverages for 5 minutes after taking the tablet [ s ee Dosage and Administration ( 2.2 ) ] .

Advise patients (or their parents/guardians) who miss more than one dose of ODACTRA to contact their healthcare professional before restarting [see Warning and Precautions ( 5.1 )] . Manufactured for: ALK-Abelló A/S ALK-Abelló A/S, Bøge Allé 6-8, DK-2970 Hørsholm, Denmark U.S. License No.

1292 Manufactured by: Catalent Pharma Solutions Limited, Blagrove, Swindon, Wiltshire, SN5 8RU UK © 2026 ALK-Abelló A/S All rights reserved. ALK

💬 Medication Guide ~3 min read ▾

MEDICATION GUIDE ODACTRA™ (OH-dack-trah) House Dust Mite ( Dermatophagoides farinae and Dermatophagoides pteronyssinus ) Allergen Extract Sublingual Tablets Carefully read this Medication Guide before you or your child starts taking ODACTRA and each time you get a refill. This Medication Guide does not take the place of talking with your healthcare provider about your or your child’s medical condition or treatment. Talk with your healthcare provider if there is something you do not understand or if you want to learn more about ODACTRA.

What is the Most Important Information I Should Know about ODACTRA? ODACTRA can cause severe allergic reactions that may be life-threatening. Stop taking ODACTRA and get medical treatment right away if you or your child has any of the following symptoms after taking ODACTRA: Trouble breathing Throat tightness or swelling Trouble swallowing or speaking Dizziness or fainting Rapid or weak heartbeat Severe stomach cramps or pain, vomiting, or diarrhea Severe flushing or itching of the skin For home administration of ODACTRA, your doctor will prescribe epinephrine, a medicine you can use if you or your child has a severe allergic reaction after taking ODACTRA.

Your doctor will train and instruct you on the proper use of epinephrine. Talk to your doctor or read the epinephrine patient information if you have any questions about the use of epinephrine. What is ODACTRA?

ODACTRA is a prescription medicine used for sublingual (under the tongue) immunotherapy to treat house dust mite allergies that can cause sneezing, runny or itchy nose, stuffy or congested nose, or itchy and watery eyes. ODACTRA may be prescribed for persons 5 through 65 years of age who are allergic to house dust mites. ODACTRA is NOT a medication that gives immediate relief for symptoms of house dust mite allergy.

Who Should Not Take ODACTRA? You or your child should not take ODACTRA if you or your child: has severe, unstable or uncontrolled asthma had a severe allergic reaction in the past that included any of these symptoms: Trouble breathing Dizziness or fainting Rapid or weak heartbeat has ever had difficulty with breathing due to swelling of the throat or upper airway after using any sublingual immunotherapy before. has ever been diagnosed with eosinophilic esophagitis. is allergic to any of the inactive ingredients contained in ODACTRA.

The inactive ingredients contained in ODACTRA are: gelatin, mannitol, and sodium hydroxide. What Should I Tell My Doctor Before Taking ODACTRA? Your doctor may decide that ODACTRA is not the best treatment if you or your child: has asthma, depending on how severe it is. suffers from lung disease such as chronic obstructive pulmonary disease (COPD). suffers from heart disease such as coronary artery disease, an irregular heart rhythm, or you or your child has hypertension that is not well controlled. is pregnant, plans to become pregnant during the time you will be taking ODACTRA, or is breast-feeding. is unable or unwilling to administer epinephrine to treat a severe allergic reaction to ODACTRA. is taking certain medicines that enhance the likelihood of a severe reaction, or interfere with the treatment of a severe reaction.

These medicines include: beta blockers and alpha-blockers (prescribed for high blood pressure) cardiac glycosides (prescribed for heart failure or problems with heart rhythm) diuretics (prescribed for heart conditions and high blood pressure) ergot alkaloids (prescribed for migraine headache) monoamine oxidase inhibitors or tricyclic antidepressants (prescribed for depression) thyroid hormone (prescribed for low thyroid activity). is receiving allergy shots or other immunotherapy under the tongue. Use of more than one of these types of medicines together may increase the likelihood of a severe allergic reaction.

You should tell your doctor if you or your child is taking or has recently taken any other medicines, including medicines obtained without a prescription and herbal… [Excerpted — this section continues on DailyMed.]

🔬 Clinical Studies ~3 min read ▾

14 CLINICAL STUDIES The efficacy of ODACTRA for the treatment of HDM-induced allergic rhinitis was investigated in three double-blind, placebo-controlled, randomized clinical field efficacy studies (Studies 1, 2, and 6) and one environmental exposure chamber (EEC) study (Study 3). Adolescents and A dults Study 1 (North American Field Efficacy Study) Study 1 was a double-blind, placebo-controlled, randomized field efficacy study conducted in the United States and Canada for a duration of up to 12 months, that compared the efficacy of ODACTRA (N=741) compared to placebo (N=741) in the treatment of HDM-induced allergic rhinitis.

Participants 12 through 85 years of age were enrolled if they had a history of symptomatic allergic rhinitis and were sensitized to D. farinae and/or D. pteronyssinus as determined by house dust mite specific IgE. Participants were required to be symptomatic and were not taking symptom-relieving allergy medications at enrollment. Participants with mild to moderate asthma, defined as asthma of a severity that required, at most, a daily medium dose of an inhaled corticosteroid, were enrolled in the study.

In this study, 31% of participants had asthma, 48% had conjunctivitis, and 76% were polysensitized to other allergens in addition to HDM, including trees, grasses, weed, animal danders and molds. The participant population was 76% White, 11% African American, 7% Asian, and 59% female. The mean age of participants was 35 years.

The efficacy of ODACTRA in the treatment of HDM-induced allergic rhinitis was assessed through self-reporting of symptoms and medication use. Based on these self-assessments, the Total Combined Rhinitis Score (TCRS), daily symptom scores (DSS) and daily medication scores (DMS) for rhinoconjunctivitis were calculated. Daily symptoms included four nasal symptoms (runny nose, stuffy nose, sneezing, and itchy nose) and two ocular symptoms (gritty/itchy eyes and watery eyes).

Each of these rhinoconjunctivitis symptoms was individually graded by participants daily on a scale of 0 (none) to 3 (severe) and then summed. Participants in active and placebo arms of this study were allowed to take symptom-relieving allergy medications (including oral and ocular antihistamines and nasal corticosteroids) during the study as needed. The DMS measured the use of these standard symptom-relieving allergy medications.

Predefined daily maximum scores were assigned to each class of rhinitis and conjunctivitis medication as 0=none, 6=oral antihistamine, 6=ocular antihistamine, and 8=nasal corticosteroid. The primary endpoint was the difference between the treatment and placebo groups in the average TCRS during approximately the last 8 weeks of treatment. The TCRS represents the sum of the daily rhinitis DSS and the rhinitis DMS.

Other secondary endpoints in this study included the average rhinitis DSS, the average rhinitis DMS, and the Total Combined Score (TCS). The TCS represents the sum of the rhinoconjunctivitis DSS and the rhinoconjunctivitis DMS, which was then averaged during approximately the last 8 weeks of treatment. Participants in this study were required to stop taking symptom-relieving allergy medication during the baseline period.

The mean rhinitis DSS at baseline was 7.94 out of 12 total points in both the treatment arm and in the placebo arm. The results of this study are shown in Table 6. Consistent results across age groups were observed, supporting a similar treatment effect in adolescent and adult subgroups.

Table 6: Total Combined Rhinitis Score (TCRS), Rhinitis Daily Symptom Score (DSS), Rhinitis Daily Medication Score (DMS), and Total Combined Score (TCS) During the Last 8 Weeks of Treatment with ODACTRA in Participants 12 Years of Age and Older (Study 1, Field Efficacy Study) Endpoint* ODACTRA (n=566) † Score ‡ Placebo (n=620) † Score ‡ Treatment Difference (ODACTRA- Placebo) Difference Relative to Placebo § Estimate (95% CI) Primary Endpoint TCRS ¶ 4.10 4.95 -0.80 -17.2% (-25.0%, -… [Excerpted — this section continues on DailyMed.]

🧪 Nonclinical Toxicology 89 words ▾

13 NONCLINICAL TOXICOLOGY

13.1Carcinogenesis, Mutagenesis, Impairment of Fertility ODACTRA has not been evaluated for carcinogenic potential or impairment of fertility in animals. Two in vitro chromosome aberration assays, an in vitro bacterial mutagenesis assay and a combined in vivo Comet and micronucleus assay for mutagenicity in rats were performed using HDM ( D. farinae and D. pteronyssinus ) allergen extracts. One in vitro chromosome aberration assay was positive.

Based on the aggregated results, the weight of evidence indicates that this finding is unlikely to be of clinical relevance.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 86 words ▾

13.1Carcinogenesis, Mutagenesis, Impairment of Fertility ODACTRA has not been evaluated for carcinogenic potential or impairment of fertility in animals. Two in vitro chromosome aberration assays, an in vitro bacterial mutagenesis assay and a combined in vivo Comet and micronucleus assay for mutagenicity in rats were performed using HDM ( D. farinae and D. pteronyssinus ) allergen extracts. One in vitro chromosome aberration assay was positive.

Based on the aggregated results, the weight of evidence indicates that this finding is unlikely to be of clinical relevance.

📄 Package Label / Principal Display Panel 56 words ▾

PRINCIPAL DISPLAY PANEL NDC 52709-1701-3 House Dust Mite ( Dermatophagoides farinae and Dermatophagoides pteronyssinus ) Allergen Extract ODACTRA Sublingual Tablets 3 blister packages of 10 tablets (30 tablets total). PRINCIPAL DISPLAY PANEL NDC 52709-1701-3 House Dust Mite (Dermatophagoides farinae and Dermatophagoides pteronyssinus) Allergen Extract ODACTRA Sublingual Tablets 3 blister packages of 10 tablets (30 tablets total).

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
30 tablets52709-1701-03 5,976 Rx · $2,452,173
Drug total (last 4 qtrs): 5,976 Rx · 210,534 units · $2,452,173 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Odactra — the program that covers self-administered drugs. 1 manufacturer.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Odactra. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$348.4K
Claims incl. refills
740
Beneficiaries
419
Spend / beneficiary
$831.58
Spend / claim
$470.86
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

About this NDC listing & data coverage

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by ALK-Abello A S. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 1 other package presentation of this same product, including 30 tablets (52709-1701-03). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
ALK-Abello A S is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.